SynCardia Co-Founder to Give Keynote Speech at Pumps & Pipes 2010

Dr. Marvin Slepian to Present on Total Artificial Heart at Collaborative Initiative Between Energy and Medicine in Houston

TUCSON, Ariz.--(BUSINESS WIRE)-- On Dec. 6, Marvin J. Slepian, M.D. (photo), Professor of Medicine (Cardiology and Biomedical Engineering) at the University of Arizona and co-founder and chairman of SynCardia Systems, Inc., manufacturer of the SynCardia temporary Total Artificial Heart, will be one of three keynote speakers at “Pumps & Pipes 4: No Boundaries,” held at the Methodist Hospital Research Institute in Houston. The goal of Pumps & Pipes is to foster and build unique research opportunities between energy and medicine – Houston’s largest industries - to enhance and develop resources and technologies.

According to the Pumps & Pipes website, “Much like moving oil through a pipeline, the heart must pump blood through vessels. Our intention is to stimulate discussion, spark ideas, explore synergies between these industries that face similar challenges in imaging, navigation, metallurgy, fluid dynamics, robotics and remote monitoring.”

“The Total Artificial Heart is an example of several unique engineering marvels,” said Dr. Slepian. “It has the shortest blood flow path (<20cm), which reduces the risk of thromboembolitic events, and the widest inflow and outflow diameters, which allows for high cardiac output (up to 9.5 L/min) while maintaining normal central venous pressure, which is essential for patient recovery.”

In addition to discussing the development and clinical use of the world’s only FDA, Health Canada and CE approved Total Artificial Heart, Dr. Slepian will also discuss the new 13.5 lb Freedom driver, the first U.S. portable driver designed to power the Total Artificial Heart both inside and outside the hospital. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.

Dr. Slepian is Director of Interventional Cardiology and Director of the Tissue Engineering Lab at the University of Arizona. He has founded numerous medical device companies and has served as acting CEO and Board Member of several medical device startups. Additionally, Dr. Slepian has conducted extensive research, development and pre-clinical investigation of novel cardiovascular therapeutic methods and devices, and is the holder of more than 25 issued and 41 filed patents.

About SynCardia Systems, Inc.

SynCardia Systems, Inc. is the Tucson-based manufacturer of the world’s only FDA, Health Canada and CE approved Total Artificial Heart: the SynCardia temporary Total Artificial Heart. There have been more than 850 implants of the Total Artificial Heart, accounting for more than 200 patient years of life on the device.

Originally used as a permanent replacement heart, the Total Artificial Heart is currently approved as a bridge to human heart transplant for people dying from end-stage biventricular failure. The Total Artificial Heart is the only device that provides immediate, safe blood flow of up to 9.5 L/min through both ventricles.

For additional information, please visit: http://www.syncardia.com

or follow SynCardia on Twitter – @SynCardia_News



CONTACT:

SynCardia Systems, Inc.
Don Isaacs
Vice President of Communications
Cell: 520-955-0660

KEYWORDS:   United States  North America  Arizona  Texas

INDUSTRY KEYWORDS:   Seniors  Women  Other Consumer  Education  University  Other Education  Energy  Other Energy  Technology  Hardware  Health  Hospitals  Medical Devices  Training  Other Science  Consumer  Science  General Health  Men

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.